Cannabis-Schedule III

Federal rescheduling of medical marijuana and marijuana-related products creates major consequences for state-licensed cannabis businesses, including tax treatment, DEA registration, compliance obligations, medical-use authorization, business continuity, and enforcement risk.

Joseph A. Bondy, PLLC advises cannabis operators, licensees, investors, and regulated businesses on the legal and practical consequences of Schedule III, state medical marijuana licensing, federal DEA registration, continued operations during review, and related regulatory and criminal-defense issues.

Rescheduling may change the federal tax treatment of qualifying cannabis businesses, but it also creates a sharper divide between compliant, licensed operators and businesses that remain exposed to regulatory or enforcement risk.

Read more about Schedule III & 280E.

The April 22, 2026 Order creates an expedited DEA registration pathway for certain state medical marijuana licensees. Timely applicants may continue covered operations during review, and DEA is directed to make every effort to process qualifying early applications within six months. 

Read more about Federal DEA Registration.

For a confidential consultation regarding Schedule III, Section 280E, DEA registration, state medical cannabis licensing, or cannabis regulatory compliance, contact Joseph A. Bondy, PLLC.